John Libbey Eurotext

Hématologie

MENU

Proteasom inhibitors in multiple myeloma: an update Volume 21, issue 6, Novembre-Décembre 2015

Figures

  • Figure 1
  • Figure 2

Tables

Authors
Hôpital Saint-Antoine,
Université Pierre et Marie Curie.
Inserm U938,
Paris
* Tirés à part

Ubiquitin-proteasome pathway plays a major role in tumor oncogenesis. Bortézomib, the first proteaseome inhibitor used in clinic has demonstrated substantial activity in the treatment of patients with multiple myeloma. Bortézomib is widely incorporated into treatment strategies across the different settings. New protéasome inhibitors have been developed, such as carfilzomib, a second-generation proteasome inhibitor or ixazomib an oral proteasome inhibitor. Both of them are now used in clinic. The aim of this short paper is to review the latest data in the field and their prospects.